Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated significant growth in its sales, with the sale of 7,233 nanochannel array flowcells in 2Q25, marking a 17% increase from the 6,165 flowcells sold in 2Q24. Adjusted revenue from consumables, software, and remaining services saw an 11% year-over-year increase in 2Q25, with a notable 16% rise in consumables and software revenues. Furthermore, the company anticipates an increase in new OGM installations for FY2025, projecting 20-25 installations compared to 15-20 in the previous year, reflecting a positive trajectory in expansion and product adoption.

Bears say

Bionano Genomics is facing a negative outlook primarily due to several financial and operational risks, including lower-than-projected market uptake and utilization of its products and systems. Despite a projected sales per share of $6.50 and net cash of $3.28 per share, the conservative EV/Revenue multiple of 1.2x suggests underlying challenges that may impede revenue growth, leading to a price objective of approximately $11. The company also faces significant financial risks, such as the inability to secure additional capital for operations and potential dilution of shares.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.